Background: IL-12 is a key mediator of antitumor immune response. In preclinical models, IT IL-12 mRNA led to IFNγ release and CD8+ T cell-dependent tumor regression and potentiated PD-L1 blockade.

TN: Triple Negative. *: safety population = enrolled population except 7 patients who did not receive at least one dose of study drug. **: Full Analysis Set = safety population except 3 patients (2 ...

You do not currently have access to this content.

AbstractBackground:. JS107 is a monomethyl auristatin E conjugated, CLDN18.2 specific ADC. JS107 exhibited potent anti-tumor activities in preclinical studies with a tolerable safety profile. Here we ...

AbstractIntroduction and Objectives:. 2141-V11 is a novel anti-CD40 antibody developed by our group, with enhanced binding to FcγRIIB that results in effective tumor-specific T-cell responses in vivo ...

Introduction: There is a need for ADC payloads with an improved therapeutic index, consequently we have coupled potent and selective inhibitors of NMT to trastuzumab to test their potential in both in ...

BACKGROUND: BTK, a non-receptor kinase in the B-cell receptor signaling pathway, plays an essential role in B-cell development and differentiation. BTK is critical for malignant B-cell survival. Oral ...

AbstractBackground:. Rinatabart sesutecan (Rina-S) is an investigational antibody-drug conjugate composed of a human monoclonal antibody that selectively binds to folate receptor alpha (FRα), a novel ...

Cancer Res (2024) 84 (7_Supplement): LB179. Breast cancer remains an unmet medical need. It has become the most occurring and deadliest cancer for women globally. Estrogen receptor (ER) is expressed ...

Abstract. Breast cancer represents the most commonly diagnosed female malignancy worldwide. Although breast cancer screening and treatments have improved significantly over the last half-century, ...

Cancer Res (2024) 84 (7_Supplement): LB236. Background: The undeniable success of CD19 CAR-T cell therapy in managing relapsed or refractory (r/r) B-cell hematological malignancies, such as diffuse ...

Abstract. Immune checkpoint blockade (ICB) has revolutionized cancer treatment, yet its efficacy in gastrointestinal malignancies is often limited by an immunosuppressive tumor microenvironment. In ...